Antitumor and antimetastatic activity of IL-23

Chia Hui Lo, Shan Chih Lee, Pin Yi Wu, Wen Yu Pan, Jui Su, Chao Wen Cheng, Steve R. Roffler, Bor Luen Chiang, Chun Nan Lee, Cheng Wen Wu, Mi Hua Tao

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

The structure and T cell stimulatory effects of the recently discovered cytokine IL-23 are similar to, but distinct from, those of IL-12. Although the antitumor activities of IL-12 are well characterized, the effect of IL-23 on tumor growth is not known. In this study, murine CT26 colon adenocarcinoma and B16F1 melanoma cells were engineered using retroviral vectors to release single-chain IL-23 (scIL-23) to evaluate its antitumor activity. In BALB/c mice, scIL-23-transduced CT26 cells grew progressively until day 26 to an average size of 521 ± 333 mm3, then the tumors started to regress in most animals, resulting in a final 70% rate of complete tumor rejection. scIL-23 transduction also significantly suppressed lung metastases of CT26 and B16F1 tumor cells. In addition, mice that rejected scIL-23-transduced tumors developed a memory response against subsequent wild-type tumor challenge. Compared with scIL-12-expressing CT26 cells, scIL-23-transduced tumors lacked the early response, but achieved comparable antitumor and antimetastatic activity. These results demonstrated that IL-23, like IL-12, provided effective protection against malignant diseases, but it probably acted by different antitumor mechanisms. As a first step in identifying these antitumor mechanisms, tumor challenge studies were performed in immunocompromised hosts and in animals selectively depleted of various lymphocyte populations. The results showed that CD8+ T cells, but not CD4+ T cells or NK cells, were crucial for the antitumor activity of IL-23.

Original languageEnglish
Pages (from-to)600-607
Number of pages8
JournalJournal of Immunology
Volume171
Issue number2
Publication statusPublished - Jul 15 2003
Externally publishedYes

Fingerprint

Interleukin-23
Neoplasms
Interleukin-12
T-Lymphocytes
Immunocompromised Host
Natural Killer Cells
Melanoma
Colon
Adenocarcinoma
Lymphocytes
Cytokines
Neoplasm Metastasis
Lung

ASJC Scopus subject areas

  • Immunology

Cite this

Lo, C. H., Lee, S. C., Wu, P. Y., Pan, W. Y., Su, J., Cheng, C. W., ... Tao, M. H. (2003). Antitumor and antimetastatic activity of IL-23. Journal of Immunology, 171(2), 600-607.

Antitumor and antimetastatic activity of IL-23. / Lo, Chia Hui; Lee, Shan Chih; Wu, Pin Yi; Pan, Wen Yu; Su, Jui; Cheng, Chao Wen; Roffler, Steve R.; Chiang, Bor Luen; Lee, Chun Nan; Wu, Cheng Wen; Tao, Mi Hua.

In: Journal of Immunology, Vol. 171, No. 2, 15.07.2003, p. 600-607.

Research output: Contribution to journalArticle

Lo, CH, Lee, SC, Wu, PY, Pan, WY, Su, J, Cheng, CW, Roffler, SR, Chiang, BL, Lee, CN, Wu, CW & Tao, MH 2003, 'Antitumor and antimetastatic activity of IL-23', Journal of Immunology, vol. 171, no. 2, pp. 600-607.
Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW et al. Antitumor and antimetastatic activity of IL-23. Journal of Immunology. 2003 Jul 15;171(2):600-607.
Lo, Chia Hui ; Lee, Shan Chih ; Wu, Pin Yi ; Pan, Wen Yu ; Su, Jui ; Cheng, Chao Wen ; Roffler, Steve R. ; Chiang, Bor Luen ; Lee, Chun Nan ; Wu, Cheng Wen ; Tao, Mi Hua. / Antitumor and antimetastatic activity of IL-23. In: Journal of Immunology. 2003 ; Vol. 171, No. 2. pp. 600-607.
@article{74985b8bec374bbea018fd5576164bcb,
title = "Antitumor and antimetastatic activity of IL-23",
abstract = "The structure and T cell stimulatory effects of the recently discovered cytokine IL-23 are similar to, but distinct from, those of IL-12. Although the antitumor activities of IL-12 are well characterized, the effect of IL-23 on tumor growth is not known. In this study, murine CT26 colon adenocarcinoma and B16F1 melanoma cells were engineered using retroviral vectors to release single-chain IL-23 (scIL-23) to evaluate its antitumor activity. In BALB/c mice, scIL-23-transduced CT26 cells grew progressively until day 26 to an average size of 521 ± 333 mm3, then the tumors started to regress in most animals, resulting in a final 70{\%} rate of complete tumor rejection. scIL-23 transduction also significantly suppressed lung metastases of CT26 and B16F1 tumor cells. In addition, mice that rejected scIL-23-transduced tumors developed a memory response against subsequent wild-type tumor challenge. Compared with scIL-12-expressing CT26 cells, scIL-23-transduced tumors lacked the early response, but achieved comparable antitumor and antimetastatic activity. These results demonstrated that IL-23, like IL-12, provided effective protection against malignant diseases, but it probably acted by different antitumor mechanisms. As a first step in identifying these antitumor mechanisms, tumor challenge studies were performed in immunocompromised hosts and in animals selectively depleted of various lymphocyte populations. The results showed that CD8+ T cells, but not CD4+ T cells or NK cells, were crucial for the antitumor activity of IL-23.",
author = "Lo, {Chia Hui} and Lee, {Shan Chih} and Wu, {Pin Yi} and Pan, {Wen Yu} and Jui Su and Cheng, {Chao Wen} and Roffler, {Steve R.} and Chiang, {Bor Luen} and Lee, {Chun Nan} and Wu, {Cheng Wen} and Tao, {Mi Hua}",
year = "2003",
month = "7",
day = "15",
language = "English",
volume = "171",
pages = "600--607",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Antitumor and antimetastatic activity of IL-23

AU - Lo, Chia Hui

AU - Lee, Shan Chih

AU - Wu, Pin Yi

AU - Pan, Wen Yu

AU - Su, Jui

AU - Cheng, Chao Wen

AU - Roffler, Steve R.

AU - Chiang, Bor Luen

AU - Lee, Chun Nan

AU - Wu, Cheng Wen

AU - Tao, Mi Hua

PY - 2003/7/15

Y1 - 2003/7/15

N2 - The structure and T cell stimulatory effects of the recently discovered cytokine IL-23 are similar to, but distinct from, those of IL-12. Although the antitumor activities of IL-12 are well characterized, the effect of IL-23 on tumor growth is not known. In this study, murine CT26 colon adenocarcinoma and B16F1 melanoma cells were engineered using retroviral vectors to release single-chain IL-23 (scIL-23) to evaluate its antitumor activity. In BALB/c mice, scIL-23-transduced CT26 cells grew progressively until day 26 to an average size of 521 ± 333 mm3, then the tumors started to regress in most animals, resulting in a final 70% rate of complete tumor rejection. scIL-23 transduction also significantly suppressed lung metastases of CT26 and B16F1 tumor cells. In addition, mice that rejected scIL-23-transduced tumors developed a memory response against subsequent wild-type tumor challenge. Compared with scIL-12-expressing CT26 cells, scIL-23-transduced tumors lacked the early response, but achieved comparable antitumor and antimetastatic activity. These results demonstrated that IL-23, like IL-12, provided effective protection against malignant diseases, but it probably acted by different antitumor mechanisms. As a first step in identifying these antitumor mechanisms, tumor challenge studies were performed in immunocompromised hosts and in animals selectively depleted of various lymphocyte populations. The results showed that CD8+ T cells, but not CD4+ T cells or NK cells, were crucial for the antitumor activity of IL-23.

AB - The structure and T cell stimulatory effects of the recently discovered cytokine IL-23 are similar to, but distinct from, those of IL-12. Although the antitumor activities of IL-12 are well characterized, the effect of IL-23 on tumor growth is not known. In this study, murine CT26 colon adenocarcinoma and B16F1 melanoma cells were engineered using retroviral vectors to release single-chain IL-23 (scIL-23) to evaluate its antitumor activity. In BALB/c mice, scIL-23-transduced CT26 cells grew progressively until day 26 to an average size of 521 ± 333 mm3, then the tumors started to regress in most animals, resulting in a final 70% rate of complete tumor rejection. scIL-23 transduction also significantly suppressed lung metastases of CT26 and B16F1 tumor cells. In addition, mice that rejected scIL-23-transduced tumors developed a memory response against subsequent wild-type tumor challenge. Compared with scIL-12-expressing CT26 cells, scIL-23-transduced tumors lacked the early response, but achieved comparable antitumor and antimetastatic activity. These results demonstrated that IL-23, like IL-12, provided effective protection against malignant diseases, but it probably acted by different antitumor mechanisms. As a first step in identifying these antitumor mechanisms, tumor challenge studies were performed in immunocompromised hosts and in animals selectively depleted of various lymphocyte populations. The results showed that CD8+ T cells, but not CD4+ T cells or NK cells, were crucial for the antitumor activity of IL-23.

UR - http://www.scopus.com/inward/record.url?scp=0037769934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037769934&partnerID=8YFLogxK

M3 - Article

C2 - 12847224

AN - SCOPUS:0037769934

VL - 171

SP - 600

EP - 607

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -